Major depression is a mood disorder that affects nearly 7% of the American population and is the most common cause of disability worldwide. Standard treatment typically involves antidepressant medication alone, although a combination of antidepressant medication and psychological treatment, such as psychotherapy or cognitive-behavioral therapy, is often more effective. However, because depression has genetic, environmental, and psychological contributing factors, treatment can be challenging. Approximately 10% of those suffering from depression have treatment-resistant depression (TRD) that does not respond to standard treatment.A number of treatment options for those with TRD target the functioning of the nervous system. Deep-brain stimulation (DBS), which is used to treat Parkinson disease, has also been investigated as a treatment for TRD. DBS involves implanting a device in the brain that sends electrical impulses to a specific area. Although the mechanism by which DBS alleviates depressive symptoms is unclear, neurostimulation provided by DBS is thought to disrupt dysfunctional patterns of electrical activity in local areas and connected brain regions.A meta-analysis reviewed the data from several studies that used different brain regions as DBS targets in the treatment of TRD. Table 1 shows the percentage of TRD patients who underwent DBS and showed clinical responsiveness and remission of depression. Clinical response was defined as a 50% reduction in scores on a measure of depression. Various scales were used in the studies, including different versions of the Hamilton Depression Rating Scale (HDRS) and Montgomery-Asberg Depression Rating Scale (MADRS). Remission of depression was defined as a score that fell below a predetermined threshold.Table 1 Percentage of TRD Patients Who Showed Clinical Response and Remission With DBS Treatment Question 35According to the monoamine hypothesis:A.abnormally high serum cortisol levels underlie most depressive symptoms.B.abnormalities in a single neurotransmitter cause most depressive symptoms.C.abnormalities in various neurotransmitters cause depressive symptoms.D.DBS would be an ineffective treatment for depressive symptoms.
Question
Major depression is a mood disorder that affects nearly 7% of the American population and is the most common cause of disability worldwide. Standard treatment typically involves antidepressant medication alone, although a combination of antidepressant medication and psychological treatment, such as psychotherapy or cognitive-behavioral therapy, is often more effective. However, because depression has genetic, environmental, and psychological contributing factors, treatment can be challenging. Approximately 10% of those suffering from depression have treatment-resistant depression (TRD) that does not respond to standard treatment.A number of treatment options for those with TRD target the functioning of the nervous system. Deep-brain stimulation (DBS), which is used to treat Parkinson disease, has also been investigated as a treatment for TRD. DBS involves implanting a device in the brain that sends electrical impulses to a specific area. Although the mechanism by which DBS alleviates depressive symptoms is unclear, neurostimulation provided by DBS is thought to disrupt dysfunctional patterns of electrical activity in local areas and connected brain regions.A meta-analysis reviewed the data from several studies that used different brain regions as DBS targets in the treatment of TRD. Table 1 shows the percentage of TRD patients who underwent DBS and showed clinical responsiveness and remission of depression. Clinical response was defined as a 50% reduction in scores on a measure of depression. Various scales were used in the studies, including different versions of the Hamilton Depression Rating Scale (HDRS) and Montgomery-Asberg Depression Rating Scale (MADRS). Remission of depression was defined as a score that fell below a predetermined threshold.Table 1 Percentage of TRD Patients Who Showed Clinical Response and Remission With DBS Treatment Question 35According to the monoamine hypothesis:A.abnormally high serum cortisol levels underlie most depressive symptoms.B.abnormalities in a single neurotransmitter cause most depressive symptoms.C.abnormalities in various neurotransmitters cause depressive symptoms.D.DBS would be an ineffective treatment for depressive symptoms.
Solution
The monoamine hypothesis suggests that abnormalities in various neurotransmitters cause depressive symptoms. Therefore, the correct answer is C. abnormalities in various neurotransmitters cause depressive symptoms.
Similar Questions
Major depression is characterized by all of the following EXCEPTdisturbances of sleep patterns.suicidal thoughts.talkativeness.diminished pleasure.
Depressive disorders are characterized by sadness severe enough or persistent enough to interfere with function and often by decreased interest or pleasure in activities.
If someone is seeking treatment for severe depression, and therapy and medication do not work, what would be the next option to help reduce the depressive symptoms?
In addition to treating mood and anxiety disorders, antidepressants are also effective for Multiple choice question.personality disorders.some eating and sleeping disorders.bipolar and obsessive-compulsive disorders.schizophrenia.
Depression is classified as what type of mental disorder?Group of answer choicesPsychotic disorderAnxiety disorderPersonality disorderMood disorder
Upgrade your grade with Knowee
Get personalized homework help. Review tough concepts in more detail, or go deeper into your topic by exploring other relevant questions.